CA2584854A1 - Carbamate compounds for use in treating neurodegenerative disorders - Google Patents
Carbamate compounds for use in treating neurodegenerative disorders Download PDFInfo
- Publication number
- CA2584854A1 CA2584854A1 CA002584854A CA2584854A CA2584854A1 CA 2584854 A1 CA2584854 A1 CA 2584854A1 CA 002584854 A CA002584854 A CA 002584854A CA 2584854 A CA2584854 A CA 2584854A CA 2584854 A1 CA2584854 A1 CA 2584854A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- group
- day
- rats
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61940204P | 2004-10-15 | 2004-10-15 | |
US60/619,402 | 2004-10-15 | ||
US69840305P | 2005-07-12 | 2005-07-12 | |
US60/698,403 | 2005-07-12 | ||
PCT/US2005/036695 WO2006044472A1 (en) | 2004-10-15 | 2005-10-14 | Carbamate compounds for use in treating neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2584854A1 true CA2584854A1 (en) | 2006-04-27 |
Family
ID=35840528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002584854A Abandoned CA2584854A1 (en) | 2004-10-15 | 2005-10-14 | Carbamate compounds for use in treating neurodegenerative disorders |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1802294A1 (ru) |
JP (1) | JP2008516961A (ru) |
KR (3) | KR20110049901A (ru) |
AU (1) | AU2005295787A1 (ru) |
BR (1) | BRPI0516112A (ru) |
CA (1) | CA2584854A1 (ru) |
EA (1) | EA200700871A1 (ru) |
EC (1) | ECSP077395A (ru) |
IL (1) | IL182432A0 (ru) |
MX (1) | MX2007004491A (ru) |
NI (1) | NI200700094A (ru) |
NO (1) | NO20072444L (ru) |
SG (1) | SG142306A1 (ru) |
WO (1) | WO2006044472A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
KR20190081385A (ko) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
CN115996905A (zh) | 2020-08-31 | 2023-04-21 | 生物药品解决方案有限公司 | 用于预防或治疗神经退行性疾病的氨基甲酸苯基烷基酯化合物 |
BR112023004354A2 (pt) | 2020-09-10 | 2023-04-04 | Bio Pharm Solutions Co Ltd | Compostos derivados de sulfamato para uso no tratamento ou alívio de um transtorno psiquiátrico |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010034365A1 (en) * | 1996-01-16 | 2001-10-25 | Choi Yong Moon | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
SK286621B6 (sk) * | 1999-08-20 | 2009-02-05 | Ortho-Mcneil Pharmaceutical, Inc. | Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva |
CA2439295C (en) * | 2001-02-27 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
KR20070057939A (ko) * | 2004-09-16 | 2007-06-07 | 얀센 파마슈티카 엔.브이. | 간질형성 및 간질을 치료하는 방법 |
-
2005
- 2005-10-14 NI NI200700094A patent/NI200700094A/es unknown
- 2005-10-14 WO PCT/US2005/036695 patent/WO2006044472A1/en active Application Filing
- 2005-10-14 JP JP2007536843A patent/JP2008516961A/ja active Pending
- 2005-10-14 CA CA002584854A patent/CA2584854A1/en not_active Abandoned
- 2005-10-14 EP EP05810159A patent/EP1802294A1/en not_active Withdrawn
- 2005-10-14 MX MX2007004491A patent/MX2007004491A/es unknown
- 2005-10-14 SG SG200802877-1A patent/SG142306A1/en unknown
- 2005-10-14 KR KR1020117007395A patent/KR20110049901A/ko not_active Application Discontinuation
- 2005-10-14 AU AU2005295787A patent/AU2005295787A1/en not_active Abandoned
- 2005-10-14 KR KR1020077010744A patent/KR20070085309A/ko active Application Filing
- 2005-10-14 BR BRPI0516112-6A patent/BRPI0516112A/pt not_active IP Right Cessation
- 2005-10-14 KR KR1020097019737A patent/KR20090130175A/ko active Search and Examination
- 2005-10-14 EA EA200700871A patent/EA200700871A1/ru unknown
-
2007
- 2007-04-10 IL IL182432A patent/IL182432A0/en unknown
- 2007-04-13 EC EC2007007395A patent/ECSP077395A/es unknown
- 2007-05-11 NO NO20072444A patent/NO20072444L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008516961A (ja) | 2008-05-22 |
IL182432A0 (en) | 2007-09-20 |
BRPI0516112A (pt) | 2008-08-26 |
KR20070085309A (ko) | 2007-08-27 |
NI200700094A (es) | 2008-02-11 |
EA200700871A1 (ru) | 2007-10-26 |
WO2006044472A1 (en) | 2006-04-27 |
MX2007004491A (es) | 2007-08-08 |
AU2005295787A1 (en) | 2006-04-27 |
EP1802294A1 (en) | 2007-07-04 |
NO20072444L (no) | 2007-06-14 |
SG142306A1 (en) | 2008-05-28 |
KR20110049901A (ko) | 2011-05-12 |
ECSP077395A (es) | 2007-05-30 |
KR20090130175A (ko) | 2009-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070021500A1 (en) | Methods for neuroprotection | |
AU2005287174B2 (en) | Use of 2-phenyl-1, 2-ethanediol- (di) carbamates for treating epileptogenesis and epilepsy | |
US20070021501A1 (en) | Methods of treating epileptogenesis | |
CA2584854A1 (en) | Carbamate compounds for use in treating neurodegenerative disorders | |
CA2439295C (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
US20080103198A1 (en) | Methods for treatment of cochlear and vestibular disorders | |
EP1809273B1 (en) | Use of 2-phenyl-1,2-ethanediol-(di)carbamates for treating epileptogenesis | |
AU2002247203B2 (en) | Carbamate compounds for use in preventing or treating neurodegenerative disordrers | |
MX2008000694A (en) | Use of 2-phenyl-l, 2-ethanedi0l-(di) carbamates for treating epileptogenesis and epilepsy | |
AU2002247203A1 (en) | Carbamate compounds for use in preventing or treating neurodegenerative disordrers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |